Effect of itraconazole on the pharmacokinetics of rosuvastatin

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 4, 2003, Pages 322-329

  Cooper, Kelvin J ^b   Martin, Paul D ^b   Dane, Aaron L ^b   Warwick, Mike J ^b   Schneck, Dennis W ^b   Cantarini, Mireille V ^a  

^a ASTRAZENECA   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; PLACEBO; ROSUVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FLUOROBENZENES; HALF-LIFE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES;

EID: 0344453812     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(02)17633-8     Document Type: Article

References (20)

1. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88:504-8.
2. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P, et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400.
3. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64:58-65.
4. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
5. Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49-53.
6. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
7. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
8. Michniewicz BM, Black AE, Sinz MW, Woolf TF. In vitro and in vivo metabolism of atorvastatin (CI-981) [abstract]. In: Proceedings of the Sixth North American International Society for the Study of Xenobiotics; 1994 Oct; Raleigh, North Carolina. Raleigh: The Society; 1994. p. 93.
9. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, et al. In vitro metabolism of simvastatin in humans (SBT) identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997;25:1191-9.
10. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999;27:173-9.
11. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin. Br J Clin Pharmacol 2003;55:94-9.
12. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42:1116-21.
13. Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract]. J Clin Pharmacol 2000;40:1056.
14. McCormick AD, McKillop D, Butters CJ, Miles GS, Baba T, Touchi A, et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol 2000;40:1055.
15. Nezasa K, Takeuchi M, Yukawa T, Kawahara M, Inazawa K, Hasegawa H, et al. Tissue specific distribution of S-4522, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, to the liver in rats [abstract]. Xenobiotic Metab Dispos 1998;13(Suppl):S226.
16. Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [abstract]. Atheroscl Suppl 2001;2:90.
17. Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002;772:219-28.
18. Tucker GT, Houston JB, Huang S-M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Clin Pharmacol Ther 2001;70:103-14.
19. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Nwose OM. Erythromycin has no clinically relevant effect on the pharmacokinetics of rosuvastatin [abstract]. Pharmacol Toxicol 2001;89(Suppl 1):75.
20. Martin PD, Kemp JV, Dane AL, Warwick MJ, Schneck DW. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 2002;42:1352-7.